269 results about "Antagonism" patented technology

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention relates to a microbial agent prepared based on a new strain of bacillus velezensis, which has the function of broad-spectrum antagonism of common pathogenic bacteria of aquatic products and can effectively prevent and / or treat bacterial diseases and / or fungal diseases of aquatic organisms including crustaceans and fishes. Meanwhile, the content of nitrite and ammonia nitrogen in aquaculture water can be effectively reduced, and the usage amount and residual quantity of antibiotics and chemical drugs in aquaculture are reduced.

The invention discloses a water quality antibiotic traceability method and system based on data analysis, and the method comprises the steps: firstly constructing a water system network into a topological graph, building a physical information-graph attention network as a pollutant propagation prediction model, and enabling the model to integrate a pollutant convective diffusion partial differential equation as a physical constraint into a loss function, the physical fidelity prediction of the spatial and temporal distribution of the antibiotic concentration in the water body is realized; secondly, constructing a pollution source tracing problem as a reverse reinforcement learning task, and reversely learning a pollution source reward function capable of optimally explaining an observation result from real downstream monitoring data by adopting an antagonism reverse reinforcement learning framework and taking the propagation prediction model as a dynamic environment through antagonism training of a generator and a discriminator; and finally, generating a probability distribution diagram of the upstream candidate pollution source position according to the reward function, and performing accurate positioning in combination with a hydrodynamic constraint condition, thereby remarkably improving the accuracy, robustness and calculation efficiency of traceability.

The invention discloses actinomucor elegans EM-27, a microbial agent and application, and belongs to the technical field of microbial application. The strain is preserved in China General Microbiological Culture Collection Center (CGMCC) on April 24, 2025, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.41924. According to the invention, an actinomucor elegans strain is separated from wheat rhizosphere, and antagonism experiments find that 8.7% of rhizosphere bacteria have antagonism on the actinomucor elegans, and 91.3% of rhizosphere bacteria and actinomucor elegans can coexist. And by applying actinomucor elegans, the growth and development of wheat can be obviously promoted. Therefore, the actinomucor elegans has a good application prospect in the aspect of improving plant growth and development.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, and a preparation method therefor and the use thereof. The compound has good TSHR antagonism, and is used in the treatment of thyroid-associated conditions and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and in the preparation of a drug for treating such conditions or diseases.

The invention discloses application of brevibacillus laterosporus in degradation of ochratoxin A, and belongs to the technical field of microbiology and biodegradation. The preservation number of the brevibacillus laterosporus is CCTCC NO: M 2022932, the brevibacillus laterosporus can degrade the ochratoxin A and prepare a product for degrading the ochratoxin A, the brevibacillus laterosporus participates in degradation of the ochratoxin A in the form of viable bacteria or fermentation liquor, and the degradation rate of the brevibacillus laterosporus to the ochratoxin A is as high as 98.26%. Besides, tests prove that the brevibacillus laterosporus has an antagonistic effect on the aspergillus ochraceus and can be used for preparing an antibacterial product of the aspergillus ochraceus, so that the ochratoxin A is treated from the source.

Provided in the present invention are a TSHR antagonist compound, a pharmaceutical composition, a preparation method therefor and the use thereof. The compound (I) has a good TSHR antagonistic effect, and is used for treating thyroid-associated disorders and / or diseases, such as hyperthyroidism, Graves' disease, Graves' ophthalmopathy, and thyroid eye disease, and for preparing drugs for such disorders or diseases.

The invention relates to the technical field of microorganisms, and particularly provides application of bacillus amyloliquefaciens BA-89 in crop growth promotion and verticillium dahliae antagonism. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.36498. The strain can secrete multiple extracellular enzymes (including protease, amylase, cellulase and glucanase), has the growth promoting characteristics of producing ammonia, dissolving potassium and the like, and can tolerate high temperature and ultraviolet stress; the compound has a remarkable antagonistic effect on various plant pathogenic bacteria (such as verticillium dahliae, fusarium oxysporum and phytophthora capsici); by inoculating the strain on cotton, the plant growth can be obviously promoted, the plant height, stem diameter, root length, leaf area and biomass are improved, and meanwhile, the disease index of verticillium wilt and the colonization amount of pathogenic bacteria at the root are effectively reduced. The strain disclosed by the invention can be used as a biological fertilizer and a biological pesticide, is used for cotton cultivation and disease prevention and control, and has a wide application prospect.

The invention relates to the field of electrocardiosignal processing, and particularly discloses an electrocardiosignal classification method, device and equipment based on multi-mode electrocardiosignal characteristics and a medium thereof.The method comprises the steps that firstly, an original electrocardiosignal is preprocessed, including denoising, resampling and heartbeat segmentation; then three types of complementary features are extracted in parallel: wavelet energy features are extracted through discrete wavelet transform, deep abstract features are extracted through a neural network comprising a multi-scale residual block, a Transform encoder and a windowed global-local attention module, a knowledge graph is constructed based on clinical prior knowledge, and clinical concept features are extracted through a graph convolutional network; adaptive weighted fusion is carried out on the three types of features through a multi-modal feature fusion module; and finally, classification is performed based on the fusion features, and an unsupervised domain adaptation strategy combining antagonism domain alignment and class condition alignment is adopted in the training process. The method effectively solves the problems that a traditional method is single in feature and insufficient in cross-domain generalization ability.

The invention belongs to the field of microorganisms, and particularly relates to trichoderma longibrachiatum CM5J-9 capable of efficiently antagonizing strawberry diseases as well as a screening method and application of the trichoderma longibrachiatum CM5J-9. The preservation number of the trichoderma longibrachiatum CM5J-9 is CGMCC (China General Microbiological Culture Collection Center) NO.41989, the trichoderma longibrachiatum CM5J-9 is preserved in the China General Microbiological Culture Collection Center on May 30, 2025, and the trichoderma longibrachiatum CM5J-9 is classified and named as trichoderma longibrachiatum. The trichoderma longibrachiatum CM5J-9 screened by the invention has a remarkable antagonistic effect on main pathogenic bacteria of strawberry continuous cropping planting soil, and has a remarkable prevention and treatment effect on strawberry related diseases caused by the main pathogenic bacteria. The trichoderma longibrachiatum CM5J-9 provided by the invention is separated from strawberry continuous cropping soil, has good environmental adaptability and disease prevention effect, is large in sporulation quantity, and has great application potential.

The invention discloses delayed coagulation type super-early-strength quick-hardening mortar and a preparation method thereof, and relates to the technical field of building materials, a shell-core structure targeted modified early strength agent is designed, a staged dry-wet mixing technology is adopted, seabed in-situ curing is combined, cooperation of mortar delayed coagulation construction and super-early-strength development is achieved, and the construction efficiency is improved. According to the present invention, with the design of the targeted modified early strength agent, the surface delayed coagulation shell and the core early strength core structure are formed through the grafting reaction of the sodium nitrite and the hydroxyl carboxylic acid monomer, and the 15-25% accurate grafting rate control is matched, such that the antagonism problem of the traditional early strength agent and the delayed coagulation agent can be solved, and the deep sea open caisson grouting temporary support requirement can be met; in the deep sea environment, the delayed coagulation shell can guarantee a construction window of 75-105 min, the requirement for long-distance grouting of the seabed is met, deep sea high pressure can trigger the delayed coagulation shell to be broken, the core early strength core rapidly activates cement to be hydrated, and the mortar can rapidly form the requirement for rapid bearing of the open caisson temporary support with enough strength.

The present invention relates to a drug carrier system in the form of nanocapsules and nanospheres loaded with luteolin and oleuropein, which have a counteracting effect on tumour cell growth, invasion and angiogenesis, and to a production method (100) of this drug carrier system.

The invention relates to the technical field of medicines, in particular to application of OpiCa1 or a nano-liposome thereof in preparation of medicines for treating and / or preventing myocardial fibrosis related diseases. The research on modeling and administration of myocardial infarction mice finds that the OpiCa1 and the nano-liposome thereof can inhibit myocardial fibrosis and improve myocardial remodeling in the myocardial remodeling period after myocardial infarction, and have a better antagonistic effect on myocardial infarction and subsequent heart failure. Further transcriptomics analysis shows that in the process of treating the myocardial infarction of mice, the OpiCa1 and the nano-liposome thereof may participate in extracellular matrix degradation in myocardial remodeling and fibrosis pathways (such as TGF-beta signal pathways) to inhibit fibrosis and improve myocardial remodeling, and the purpose of relieving deterioration of the myocardial infarction is achieved.

The invention provides application of bifidobacterium breve in preparation of a product for resisting gastric ulcer and gastric inflammation caused by helicobacter pylori, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium breve NKU BB1-2 is GDMCC NO: 65956, and the bifidobacterium breve NKU BB1-2 can antagonize helicobacter pylori colonization and relieve gastric ulcer aggravation caused by helicobacter pylori. The bifidobacterium breve NKU BB 1-2 has good helicobacter pylori antagonism ability in an in-vitro environment, and can significantly inhibit colonization growth of helicobacter pylori; animal experiments show that the bifidobacterium breve NKU BB 1-2 can relieve gastric ulcer aggravation caused by helicobacter pylori infection in vivo, and the gastric mucosa lesion is relieved, the stomach inflammation is relieved, and the stomach pH value is increased; in addition, the bifidobacterium breve NKU BB1-2 can also significantly improve the diversity of stomach microorganisms, regulate and improve the structure of the stomach microorganisms, and assist antagonism and removal of helicobacter pylori infection.

The invention provides an endophyte Gliocladium roseum NG-12, which is named as Gliocladium roseum NG-12, and the preservation number of the endophyte Gliocladium roseum NG-12 is CGMCC (China General Microbiological Culture Collection Center) No. 41801. The endophyte Gliocladium roseum NG-12 provided by the invention has good root-knot nematode killing activity and antibacterial activity, has a good antagonistic effect on various plant pathogens such as fusarium oxysporum, colletotrichum gloeosporioides and colletotrichum gloeosporioides, is a potential biological preparation for preventing and treating root-knot nematode diseases, fusarium wilt, anthracnose and the like, and also has the effects of dissolving potassium, fixing nitrogen, dissolving phosphorus, preventing and treating the root-knot nematode diseases and the like. The capability of producing siderophore, protease and cellulase is realized. The gliocladium roseum provided by the invention has a wide development space and a good development and application prospect.

The present invention relates to a novel anti-CD40 antibody and use thereof and, more specifically, to a novel anti-CD40 antibody and use thereof, wherein the antibody comprises a complementarity determining region of a specific sequence and exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling. The novel anti-CD40 antibody of the present invention exhibits an excellent antagonistic effect by blocking CD40-CD40L signaling, and thus can be widely used as a preparation for preventing or treating various diseases, such as autoimmune diseases and chronic inflammatory diseases, and as a preparation for inhibiting immune rejection at the time of transplantation.

The invention discloses staphylococcus xylosus and application of the staphylococcus xylosus in antagonism of ralstonia solanacearum, and relates to the technical field of agricultural biological control, the staphylococcus xylosus CQZY-H-XJ-0002 provided by the invention is preserved in Guangdong Microbial Culture Collection Center on October 14, 2024, and the preservation number of the strain is GDMCC NO.65264. The staphylococcus xylosus CQZY-H-XJ-0002 provided by the invention is named as KQZY-H-XJ-0002. The staphylococcus xylosus CQZY-H-XJ-0002. The strain has a remarkable effect of inhibiting the growth of ralstonia solanacearum, and can effectively prevent and treat bacterial wilt and promote plant growth. The strain has the advantages of being simple in process, easy to operate, low in cost, green, safe, non-toxic and the like when being used for biological control.

The invention discloses bacillus subtilis Bs1 as well as an antagonistic substance and application thereof. According to the invention, Bs1 with antagonism on colletotrichum gloeosporioides is separated and screened for the first time, an antagonistic substance is clear as Bs1 serine-producing protease Vpr, a Bs1 bacteriostasis mechanism and biological control potential excavation are analyzed in a multi-omics manner, a peripheral colonization rule of Bs1-Rif is clear, and an indoor control strategy of the strain Bs1 on cunninghamia lanceolata anthracnose is optimized. When the strain Bs1 is applied on the day when pathogenic bacteria are inoculated, a certain prevention and treatment effect is achieved, and it is indicated that the strain Bs1 can rapidly occupy the ecological niche; the average antibacterial rate of the strain Bs1 can reach 66.69%. The biocontrol strain and theoretical basis are provided for prevention and control of Chinese fir diseases, the application of biological prevention and control in forestry is promoted, the interaction mechanism of biocontrol bacteria and pathogenic bacteria can be deeply understood, and the sustainable development requirement of modern forestry is met.

The invention discloses Erwinia phyllostachys ZX-13 and application thereof in antagonism of epidemic disease pathogenic bacteria of Eupin, and belongs to the technical field of microorganisms. The invention discloses a Erwinia phyllostachys ZX-13, and the preservation number of the Erwinia phyllostachys ZX-13 is GDMCC No: 66800. The Erwinia phyllostachys ZX-13 disclosed by the invention can be used for preventing and treating the epidemic disease of the elaphus japonicus caused by the cryptophyton pseudophyllanthus of the elaphus japonicus; the Erwinia rhizosphere ZX-13 is a biological control potential strain with good antagonism effect, high control effect and good environmental safety, and has good development and application prospects.

In various examples, a technique for processing sensor data includes generating, using a machine learning model and based on a first instance of sensor data, a first set of confidence for a set of output types, and a first antagonism confidence representing a likelihood that the first instance of sensor data is antagonistic. The technique further includes determining, based on the first antagonism confidence, that the first sensor data instance is antagonistic. The technique further includes transmitting a first indication to one or more downstream components indicating that the first instance of sensor data is antagonistic, such that the one or more downstream components perform one or more operations based at least on the indication.

The invention discloses bacillus velezensis Bve1910, which is preserved in the China Center for Type Culture Collection (CCTCC) and has the preservation number of CCTCC NO. M 20221965. The strain and metabolites thereof have strong antagonistic effects on more than ten types of marine culture animal pathogenic bacteria such as vibrio harveyi, vibrio erwiniae, vibrio canbayi, vibrio parahaemolyticus, vibrio alginolyticus, vibrio anguillarum, vibrio cholerae, vibrio shewanii, vibrio rotifer, pseudoalteromonas and photobacterium damarae, are strong in antibacterial activity and wide in antibacterial spectrum, and can be used for preparing marine culture animal pathogenic bacteria. According to the preparation method, the traditional Chinese medicine composition is simple in preparation method and rich and stable in metabolite, an ammonium sulfate precipitation extract, a hydrochloric acid precipitation methanol extraction extract, an ethyl acetate extraction extract and a chloroform extraction extract all have a broad-spectrum bacteriostatic effect, functional substances playing the broad-spectrum antagonistic bacteriostatic effect are compounded and diversified, and the directional selection effect on bacteria in the environment and ecology is not generated; and pathogenic bacteria are not easy to generate tolerance, so that the method has good application safety and ecological safety properties.

The invention discloses a low-temperature-resistant pseudomonas with a biocontrol effect and application thereof, relates to the field of microorganisms, and aims to solve the problem that the pathogen antagonism capability is reduced due to the fact that the activity of the existing biocontrol strain is inhibited in a low-temperature environment. The pseudomonas is pseudomonas koreana B12, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation date is February 17, 2025, and the preservation number is CGMCC No.33538. The pseudomonas koreana B12 can be applied to the field of biological engineering. The low-temperature-resistant pseudomonas disclosed by the invention is used for inhibiting phytopathogens at a low temperature of 5-15 DEG C and is used for decomposing organic phosphorus, glucan, starch and cellulose.

The invention provides an anti-PD-1 antibody, a CAR-T cell, and a preparation method and application thereof. The anti-PD-1 antibody comprises LCDR-1-3 as shown in SEQ ID NO: 1-3 and HCDR-1-3 as shown in SEQ ID NO: 4-6, respectively. The CAR-T cell expresses a novel element for efficiently blocking the PD-1, and the element is a single-chain antibody for targeting the PD-1 in a cell membrane anchoring manner. And the chimeric antigen receptor and the cell membrane anchored anti-PD-1 scFv are connected by a 2A cleavage protein. The membrane anchor type anti-PD-1 scFv expressed by the CAR-T cell can almost completely block the expression of PD-1 on the surface of a T cell membrane, and further block a signal channel combined with PD-1 / PD-L1, so that the capability of T cell depletion caused by antagonism tumor of the CAR-T cell is enhanced, and the purpose of enhancing the anti-tumor effect of the CAR-T cell is achieved.

Compositions comprising anti-PD-1 antibodies and related methods for treating cancer and other disorders responsive to PD-1 antagonism are provided.SOLUTION: A composition comprising an oxidized variant of an anti-PD-1 antibody, wherein the oxidized variant comprises a heavy chain amino acid sequence comprising CDRH1-3 each consisting of a specific amino acid sequence and a light chain amino acid sequence comprising CDRL1-3 each consisting of a specific amino acid sequence; wherein the composition comprises no more than 65% oxidized variants.SELECTED DRAWING: None

The invention discloses bacillus subtilis, a complex microbial inoculant and application of the complex microbial inoculant to degradation of mycotoxin, and belongs to the field of microorganisms and fermentation engineering. According to the invention, a strain of bacillus subtilis BLYC-1937 with the activity of degrading mycotoxin is obtained through screening, and the bacillus subtilis BLYC-1937 has a good degradation effect on pollution of single toxin of T-2 toxin, vomitoxin, fumonisins B1, aflatoxin B1 and ochratoxin A or combined pollution of multiple toxins; the strain has good antagonism on fusarium oxysporum capable of producing T-2 toxin and aspergillus ochraceus capable of producing ochratoxin A, and pollution of T-2 toxin and ochratoxin A can be reduced from the source.

The invention relates to a drug combination data processing method and system based on organ adverse reactions, and the method comprises the steps: carrying out the graph neural network fusion of multi-source patient medical data, and carrying out the cross-scale integration of organ function parameters, metabolic characteristics and hemodynamic data; extracting a core biomarker by utilizing principal component analysis and organ specificity screening, and generating a feature vector representing organ reaction; constructing a nonlinear drug interaction model by combining a dose-time sequence and in-vitro experimental data, and quantifying the strength of synergy and antagonism; gene expression profiles, pathological states and lifestyle data are introduced for triple dynamic calibration, and individualized adverse reaction probability optimization is achieved; monte Carlo sampling is adopted to simulate an organ toxicity scene, and intelligent classification decision is performed on a high-risk combination scheme based on a supervision rule base. The method breaks through the limitation of data islands, static evaluation and individualization deficiency in the traditional technology, and significantly improves the prediction precision and clinical applicability of the drug combination safety.

The present invention discloses an actinomycete with antagonistic effect against the pathogen of cucumber damping-off and its application. The actinomycete is Streptomyces aureusensis Q1C-44, which has antagonistic effect against Rhizoctonia solani of cucumber, can effectively inhibit the hyphal elongation of the pathogenic fungus, and can be used to control damping-off caused by Rhizoctonia solani of cucumber.

The invention provides a composition with an effect of improving iron-deficiency anemia as well as a preparation method and application of the composition, and belongs to the technical field of pharmaceutical compositions. The composition with the effect of improving iron-deficiency anemia, provided by the invention, is prepared from the following raw materials in parts by weight: 15 to 20 parts of radix astragali seu hedysari extract, 5 to 10 parts of fructus jujubae extract, 2 to 5 parts of radix paeoniae alba extract, 4 to 8 parts of radix angelicae sinensis extract and 8 to 16 parts of ethylenediaminetetraacetic acid ferric sodium salt. The defect of single effect in the prior art is broken through, the synergistic effect of the four effects of improving iron-deficiency anemia, helping sleep, improving acne and protecting gastric mucosa is achieved through scientific compatibility, the conditioning requirements of crowds with multiple diseases can be met without taking multiple products, the eating burden is reduced, meanwhile, the antagonistic effect among different product components is avoided, and the health-care product is suitable for being popularized and applied. The overall conditioning effect can be improved.

Methods of improving nutrition in subjects, including individuals who have undergone gastrointestinal surgery, by avexitide therapy are disclosed. Avexitide may be administered subcutaneously or intravenously as a part of a liquid pharmaceutical formulation. Avexitide therapy may improve weight and / or nutritional intake / status in subjects.

Provided are a compound having serotonin 5-HT2A receptor antagonism and / or inverse agonism, a pharmaceutically acceptable salt thereof, and a composition for serotonin 5-HT2A receptor antagonism and / or inverse agonism comprising them.A compound represented by Formula (I):wherein R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is each independently a hydrogen atom or the like; R3 is each independently a hydrogen atom or the like; n is 1 or the like; a combination of (L1, L2) is (NH, N) or the like; R4 is a group represented by Formula:wherein p and q are each independently 2 or the like; Ra is substituted or unsubstituted alkyl or the like; Xb is each independently CRbRb′; Rb is each independently a hydrogen atom or the like; Rb′ is each independently a hydrogen atom or the like; Xc is each independently CRcRc′; Rc is each independently a hydrogen atom or the like; Rc′ is each independently a hydrogen atom or the like; Xd is CRd or the like; and Rd is a hydrogen atom or the like; R5 and R6 are each independently a hydrogen atom or the like; and R7 is a group represented by Formula:wherein A is CR11 or the like; R9 is substituted or unsubstituted alkyloxy or the like; R10 is a hydrogen atom or the like; and R11 is each independently a hydrogen atom or the like; or a pharmaceutically acceptable salt thereof.